Subscribe

Onyx Healthcare Inc. (6569.TWO)

TWD99.80 -0.20 (-0.20%)
TW TWO Healthcare Medical - Devices
Address No.135, Lane 235 231
New Taipei City, TW
CEO John Chuang
Website onyx-healthcare.com
IPO 2016-01-15
ISIN TW0006569007

Explore sections of this company profile

Description

Onyx Healthcare Inc. is a dedicated Taiwanese firm specializing in medical information technology. The company focuses on the entire lifecycle—from conceptual design and manufacturing to the commercial distribution—of medical computing hardware and peripherals, primarily targeting the hospital and clinical IT markets within Taiwan. Their extensive product lineup encompasses a variety of advanced solutions, such as AI-enabled medical PCs and tablets, specialized computer and monitor setups for digital operating rooms and telemedicine, and adaptable medical cart computers. They also offer robust medical power panel PCs, power banks, and sophisticated battery management systems. Further offerings include portable medical tablets, professional slim and powerful all-in-one PCs, medical displays and integrated computing solutions for medical devices, as well as motherboards and industrial-grade PCs and tablets, alongside healthcare infotainment systems. In addition to their core products, Onyx Healthcare provides custom Original Design Manufacturing (ODM) and Original Equipment Manufacturing (OEM) services. Established in 2010, the company is headquartered in New Taipei City, Taiwan, and operates as a subsidiary of AAEON Technology Inc.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
TWD99.80 -0.20 (-0.20%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
106.5K
Beta
0.27
Float Shares
19.90M
Free Float %
50.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.50% +0.00% -0.99% +1.41% -12.23% -8.22% -21.79% +7.50% +0.65% -15.28% +58.79%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
99.80
DCF (Unlevered) 60.75 -39.1%
DCF (Levered) 61.70 -38.2%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.19
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Devices: +11.2%
    +5.8% Q1'26: +21.8% (vs Q1'25)
  • ✗
    EPS growth Medical - Devices: +28.5%
    -38.1% Q1'26: +442.1% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Devices: +30.9%
    +6.3% Q1'26: +7.1% (vs Q1'25)
  • ✗
    EBIT margin Medical - Devices: +6.2%
    +4.0% Q1'26: +7.8% (vs Q1'25)
  • ✗
    ROIC Medical - Devices: +3.3%
    +3.2% Q1'26: +6.4% (vs Q1'25)
  • ✓
    Share dilution Medical - Devices: 0.0%
    -0.4% ★ Q1'26: +0.5% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    5.61× ★ Q1'26: 2.47× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.28) × ERP
WACC = 93% × Ke + 7% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 59.84 Current price: 99.80
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana. 		Dec 2031
1 Rev. Ana.
1 EPS Ana.
Revenue
1.10B
est.
1.29B
est.
1.42B
est.
1.48B
est: 1.69B (-12.4%)
1.35B
est: 1.32B (+1.9%)
1.20B
est: 1.33B (-9.6%)
1.24B
est: 1.10B (+13.4%)
1.31B
est: 1.29B (+2.2%)
1.29B
1.29B – 1.29B
+0.0% YoY
1.42B
1.42B – 1.42B
+10.1% YoY
1.69B
1.69B – 1.69B
+19.6% YoY
1.32B
1.32B – 1.32B
-21.9% YoY
1.33B
1.33B – 1.33B
+0.6% YoY
1.65B
1.65B – 1.65B
+23.9% YoY
EBITDA
184.36M
est.
216.35M
est.
238.24M
est.
251.31M
est: 284.87M (-11.8%)
235.87M
est: 222.58M (+6.0%)
170.68M
est: 223.93M (-23.8%)
164.37M
est: 154.73M (+6.2%)
52.24M
est: 181.58M (-71.2%)
181.58M
181.58M – 181.58M
+0.0% YoY
199.95M
199.95M – 199.95M
+10.1% YoY
239.09M
239.09M – 239.09M
+19.6% YoY
186.81M
186.81M – 186.81M
-21.9% YoY
187.94M
187.94M – 187.94M
+0.6% YoY
232.78M
232.78M – 232.78M
+23.9% YoY
EBIT
163.66M
est.
192.06M
est.
211.49M
est.
236.63M
est: 252.89M (-6.4%)
203.09M
est: 197.59M (+2.8%)
142.75M
est: 198.78M (-28.2%)
143.67M
est: 138.95M (+3.4%)
52.24M
est: 163.05M (-68.0%)
163.05M
163.05M – 163.05M
+0.0% YoY
179.55M
179.55M – 179.55M
+10.1% YoY
214.70M
214.70M – 214.70M
+19.6% YoY
167.75M
167.75M – 167.75M
-21.9% YoY
168.76M
168.76M – 168.76M
+0.6% YoY
209.03M
209.03M – 209.03M
+23.9% YoY
Net Income
151.08M
est.
137.64M
est.
233.85M
est.
239.38M
est: 269.93M (-11.3%)
167.08M
est: 170.98M (-2.3%)
127.55M
est: 154.28M (-17.3%)
180.91M
est: 150.50M (+20.2%)
111.70M
est: 137.11M (-18.5%)
137.11M
137.11M – 137.11M
+0.0% YoY
232.95M
232.95M – 232.95M
+69.9% YoY
268.90M
268.90M – 268.90M
+15.4% YoY
170.33M
170.33M – 170.33M
-36.7% YoY
153.69M
153.69M – 153.69M
-9.8% YoY
168.64M
168.64M – 168.64M
+9.7% YoY
SGA
190.49M
est.
223.54M
est.
246.15M
est.
225.62M
est: 294.34M (-23.3%)
232.16M
est: 229.98M (+0.9%)
208.96M
est: 231.37M (-9.7%)
247.47M
est: 152.75M (+62.0%)
—
est: 179.25M (-100.0%)
179.25M
179.25M – 179.25M
+0.0% YoY
197.39M
197.39M – 197.39M
+10.1% YoY
236.03M
236.03M – 236.03M
+19.6% YoY
184.42M
184.42M – 184.42M
-21.9% YoY
185.53M
185.53M – 185.53M
+0.6% YoY
229.80M
229.80M – 229.80M
+23.9% YoY
EPS
3.88
est.
3.54
est.
6.01
est.
6.88
est: 6.93 (-0.8%)
4.74
est: 4.39 (+7.9%)
3.67
est: 3.96 (-7.4%)
4.69
est: 3.88 (+20.9%)
2.88
est: 3.54 (-18.5%)
3.54
3.54 – 3.54
+0.0% YoY
6.01
6.01 – 6.01
+69.9% YoY
6.93
6.93 – 6.93
+15.4% YoY
4.39
4.39 – 4.39
-36.7% YoY
3.96
3.96 – 3.96
-9.8% YoY
4.35
4.35 – 4.35
+9.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-13 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-12 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-11 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-08 B 3/5 3/5 3/5 4/5 2/5 2/5 3/5
2026-05-07 B 3/5 3/5 3/5 4/5 2/5 2/5 3/5
2026-05-06 B 3/5 3/5 3/5 4/5 2/5 2/5 3/5
2026-05-05 B 3/5 3/5 3/5 4/5 2/5 2/5 3/5
2026-05-04 B 3/5 3/5 3/5 4/5 2/5 2/5 3/5
2026-04-30 B 3/5 3/5 3/5 4/5 2/5 2/5 3/5
2026-04-29 B+ 3/5 3/5 3/5 5/5 2/5 2/5 3/5
2026-04-28 B+ 3/5 3/5 3/5 5/5 2/5 2/5 3/5
2026-04-27 B+ 3/5 3/5 3/5 5/5 2/5 2/5 3/5
2026-04-24 B+ 3/5 3/5 3/5 5/5 2/5 2/5 3/5
2026-04-23 B+ 3/5 3/5 3/5 5/5 2/5 2/5 3/5
2026-04-22 B+ 3/5 3/5 3/5 5/5 2/5 2/5 3/5
2026-04-21 B 3/5 3/5 3/5 5/5 1/5 2/5 3/5
2026-04-20 B 3/5 3/5 3/5 5/5 1/5 2/5 3/5
2026-04-17 B+ 3/5 4/5 3/5 5/5 1/5 2/5 3/5
2026-04-16 B+ 3/5 4/5 3/5 5/5 1/5 2/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
197.03M
OE per share TTM
5.05
Owner's Yield
5.01%
Maintenance CapEx ratio
6.44%
Maint CapEx / Avg PPE
16.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 1 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Avantis Emerging Markets Equity ETF AVEM 0.00% 29.8K 0.33%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
435.4K
Shares Outstanding
39.07M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Hsiang-Chih Yang Head of Accounting — female
Hsing-Kuo Chao Head of Product R&D Division — male
John Chuang President — —
Ying-Te Chen Director of Product & Marketing — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Devices